Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).

被引：1
|
作者：
Nakamura, Masato
Yamada, Yasuhide
Takahari, Daisuke
Matsumoto, Hiroshi
Baba, Hideo
Yoshida, Kazuhiro
Yoshida, Motoki
Iwamoto, Shigeyoshi
Shimada, Ken
Komatsu, Yoshito
Sasaki, Yasutsuna
Satoh, Taroh
Takahashi, Keiichi
Mishima, Hideyuki
Muro, Kei
Watanabe, Masahiko
Sakata, Yuh
Morita, Satoshi
Shimada, Yasuhiro
Sugihara, Kenichi
机构：
[1] Aizawa Hosp, Matsumoto, Nagano, Japan
[2] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan
[3] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[5] Kumamoto Univ, Kumamoto, Japan
[6] Gifu Univ, Sch Med, Dept Surg Oncol, Gifu 500, Japan
[7] Osaka Med Coll Hosp, Ctr Canc Chemotherapy, Osaka, Japan
[8] Kansai Med Univ, Takji Hosp, Dept Surg, Moriguchi, Osaka 570, Japan
[9] Saitama Med Univ, Hidaka, Japan
[10] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido 060, Japan
[11] Showa Univ, Tokyo, Japan
[12] Osaka Univ, Osaka, Japan
[13] Komagome Hosp, Dept Surg, Tokyo Metropolitan Canc, Tokyo, Japan
[14] Komagome Hosp, Ctr Infect Dis, Tokyo, Japan
[15] Aichi Med Univ, Unit Canc Ctr, Nagakute, Aichi 48011, Japan
[16] Kitasato Univ, Sch Med, Sagamihara, Kanagawa 228, Japan
[17] Misawa City Hosp, Misawa, Japan
[18] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[19] Tokyo Med & Dent Univ, Grad Sch, Dept Surg Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.3586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3586
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer [SOFT Study Group]
    Matsumoto, H.
    Yamada, Y.
    Takahari, D.
    Baba, H.
    Yoshida, K.
    Komatsu, Y.
    Satoh, T.
    Muro, K.
    Shimada, Y.
    Sugihara, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S486 - S487
  • [2] A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study.
    Takahari, Daisuke
    Yamada, Yasuhide
    Matsumoto, Hiroshi
    Baba, Hideo
    Yoshida, Kazuhiro
    Nakamura, Masato
    Yoshida, Motoki
    Iwamoto, Shigeyoshi
    Takinishi, Yasutaka
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Komatsu, Yoshito
    Sasaki, Yasutsuna
    Satoh, Taroh
    Takahashi, Keiichi
    Mishima, Hideyuki
    Muro, Kei
    Watanabe, Masahiko
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, noninferiority, randomised phase III: SOFT study
    Baba, Hideo
    Yamada, Yasuhide
    Takahari, Daisuke
    Matsumoto, Hiroshi
    Yoshida, Kazuhiro
    Nakamura, Masato
    Yoshida, Motoki
    Iwamoto, Shigeyoshi
    Shimada, Ken
    Komatsu, Yoshito
    Sasaki, Yasutsuna
    Satoh, Taroh
    Takahashi, Keiichi
    Mishima, Hideyuki
    Muro, Kei
    Watanabe, Masahiko
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Sugihara, Kenichi
    ESMO OPEN, 2017, 2 (01)
  • [4] SUNITINIB PLUS 5-FLUOROURACIL, LEUCOVORIN AND OXALIPLATIN (MFOLFOX6) VS. BEVACIZUMAB PLUS MFOLFOX6 IN FRST-LINE METASTATIC COLORECTAL CANCER (MCRC) - INTERIM RESULTS OF A RANDOMIZED, PHASE IIB STUDY
    Hecht, J.
    Yoshino, T.
    Mitchell, E.
    Dees, M.
    Kroening, H.
    Patel, R.
    Welslau, M.
    Dakhil, S.
    Yamazaki, K.
    Maneval, Chow E.
    Kretzschmar, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 15 - 15
  • [5] A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 ns first-line treatment for metastatic colorectal cancer (mCRC); Interim results.
    Hecht, J. R.
    Yoshio, T.
    Mitchell, E. P.
    Dees, M. S., III
    Countouriotis, A. M.
    Maneval, E. C.
    Kretzschmar, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
    Yamada, Yasuhide
    Takahari, Daisuke
    Matsumoto, Hiroshi
    Baba, Hideo
    Nakamura, Masato
    Yoshida, Kazuhiro
    Yoshida, Motoki
    Iwamoto, Shigeyoshi
    Shimada, Ken
    Komatsu, Yoshito
    Sasaki, Yasutsuna
    Satoh, Taroh
    Takahashi, Keiichi
    Mishima, Hideyuki
    Muro, Kei
    Watanabe, Masahiko
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Sugihara, Kenichi
    LANCET ONCOLOGY, 2013, 14 (13): : 1278 - 1286
  • [7] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
    van Hazel, Guy A.
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget A.
    Strickland, Andrew H.
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan
    Boucher, Eveline
    Tichler, Thomas
    Shacham-Shmueli, Einat
    Powell, Alex
    Eliadis, Paul
    Isaacs, Richard
    Price, David
    Moeslein, Fred
    Taieb, Julien
    Bower, Geoff
    Gebski, Val
    Van Buskirk, Mark
    Cade, David N.
    Thurston, Kenneth
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
  • [8] MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)
    Schmoll, H.
    Cunningham, D.
    Sobrero, A.
    Karapetis, C.
    Rougier, P.
    Koski, S. L.
    Barker, P.
    Mookerjee, B.
    Robertson, J.
    van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 189 - 189
  • [9] S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
    Yamada, Y.
    Denda, T.
    Gamoh, M.
    Iwanaga, I.
    Yuki, S.
    Shimodaira, H.
    Nakamura, M.
    Yamaguchi, T.
    Ohori, H.
    Kobayashi, K.
    Tsuda, M.
    Kobayashi, Y.
    Miyamoto, Y.
    Kotake, M.
    Shimada, K.
    Sato, A.
    Morita, S.
    Takahashi, S.
    Komatsu, Y.
    Ishioka, C.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 624 - 631
  • [10] Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC).
    Otsuji, Toshio
    Yamazaki, Kentaro
    Ojima, Hitoshi
    Kuwano, Hiroyuki
    Kato, Takeshi
    Shimada, Ken
    Denda, Tadamichi
    Esaki, Taito
    Hyodo, Ichinosuke
    Boku, Narikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345